Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance Eli Lilly And Co (NYSE: LLY) has Benzinga · Feb 3, 2022
Eli Lilly: Q4 Earnings Insights Eli Lilly (NYSE:LLY) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:25 AM. Here's what investors need to know about the announcement. Benzinga · Feb 3, 2022
A Preview Of Eli Lilly's Earnings Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Eli Lilly will likely report an Earnings Per Share (EPS) of $2.19. Benzinga · Feb 2, 2022
Looking At Eli Lilly's Recent Whale Trades Benzinga's options scanner just detected over 12 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $597,272. At the same time, our algo caught 7 for a total amount of 518,954. Benzinga · Feb 1, 2022
Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to Benzinga · Jan 28, 2022
Michigan AG to investigate Eli Lilly insulin prices, but state courts could prove an obstacle Michigan Attorney General Dana Nessel plans to investigate Eli Lilly's insulin pricing but will have to first overturn Michigan court precedent in order to push forward with the probe. Tribune News Service · Jan 27, 2022
What Are Whales Doing With Eli Lilly A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 13 strange trades. Benzinga · Jan 25, 2022
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin Benzinga · Jan 25, 2022
FDA halts use of antibody drugs that don't work vs. omicron U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant The Independent UK · Jan 24, 2022
If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 12.31% on an annualized basis. Benzinga · Jan 24, 2022
Expert Ratings For Eli Lilly Over the past 3 months, 7 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Benzinga · Jan 21, 2022
Looking Into Eli Lilly and Company's Recent Short Interest Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 4.0% since last its last report. The company recently reported that it has 6.19 million shares sold short, which is 0.78% of all regular shares that are available for trading. Benzinga · Jan 21, 2022
Looking At Eli Lilly's Recent Whale Trades A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades. Benzinga · Jan 20, 2022
The Best Health Care ETFs to Buy The best health care ETFs offer diversification across medical industries as well as exposure to a sector with lower volatility than the broader market. Kiplinger · Sep 1, 2021